Shenzhen - Delayed Quote CNY

ELECTRICAL APPARATUS SCIENCE ACADEMY (300215.SZ)

5.26

-0.13

(-2.41%)

At close: May 30 at 3:04:07 PM GMT+8

Dollar General, Lululemon, Broadcom: Earnings to Watch This Week

Asking for a Trend's Josh Lipton takes a look ahead to this week's biggest earnings releases, including chipmaker Broadcom (AVGO), Lululemon Athletica (LULU), CrowdStrike Holdings (CRWD), Hewlett Packard Enterprise (HPE), and discount retailers Dollar General (DG), Dollar Tree (DLTR), and Five Below (FIVE). To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.

Yahoo Finance Video 18 hours ago

LULU

VSCO

RBRK
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint.

PR Newswire 1 hour ago

BPMC

SNY

SNYNF
Sanofi buys US biopharma group Blueprint in $9.1 billion deal

PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion.

Reuters 1 hour ago

SNY

BPMC
Singapore Dollar Strengthens Slightly, Aided by U.S. Steel, Aluminum Tariffs

The Singapore dollar strengthened slightly against its U.S. counterpart in the Asian session, aided by President Trump’s announcement that he would double tariffs on steel and aluminum imports to 50% from June 4.

The Wall Street Journal 3 hours ago

X
Watch These U.S. Steel Stock Price Levels as Trump Plans to Double Steel Tariffs

U.S. Steel shares will be in the spotlight to start the week after President Donald Trump on Friday said he plans to double steel and aluminum tariffs to 50%. Monitor these key chart levels.

Investopedia 4 hours ago

X
If EPS Growth Is Important To You, DocuSign (NASDAQ:DOCU) Presents An Opportunity

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Simply Wall St. 16 hours ago

DOCU
2 American Companies That Could Be the Winners of Trump's Tariff Wars

Trump's tariff wars have brought outsize uncertainty to the stock market, making it increasingly challenging to identify companies positioned to weather the storm.

Motley Fool 19 hours ago

HD

NUE
Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week.

Investing.com 20 hours ago

CLF

MSM

FICO
5 Brilliant Stocks to Buy in June

Nvidia and Taiwan Semiconductor are still benefiting from the AI race. Alphabet and Adobe are beaten down due to fears of AI replacing them. Amazon investors should be focused on cloud computing, not commerce.

Motley Fool 21 hours ago

ADBE

NVDA

TSM
TSMC Stock Maintains High-Conviction AI Play Status With $220 Price Target

Taiwan Semiconductor Manufacturing Company (TSM), or TSMC for short, the world’s numero uno pure-play semiconductor foundry, has surged nearly 20% over the past month. Despite this impressive rally, my outlook remains bullish. The company is well-positioned to benefit from powerful tailwinds, including relentless AI-driven demand, a dominant—nearly monopolistic—position in advanced chip manufacturing, ongoing geographic diversification, and a steady cadence of technological breakthroughs. Unveil

TipRanks yesterday

INTC

TSM

TSMWF
MP Materials (NYSE:MP) Reports Q1 Net Loss Despite Increase In REO Production

MP Materials (NYSE:MP) recently signed a Memorandum of Understanding with the Saudi Arabian Mining Company to develop a rare earth supply chain in Saudi Arabia, aligning with growing global demands. Despite reporting a net loss for the first quarter, the company increased its REO and NdPr production volumes. Additionally, no shares were repurchased in the recent buyback tranche, reflecting existing efforts. Over the past week, the company's share price rose by 11%, notably outperforming the...

Simply Wall St. yesterday

MP
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities. Despite these positive developments, the company's shares fell by 17% last week. In contrast, the broader market rose by 1.7%. This divergence might suggest that the market's reaction to Regeneron's news was mixed or that other factors were at play. While the trial success and new partnership could...

Simply Wall St. yesterday

REGN
Better AI Stock: Palantir vs. BigBear.ai

Palantir and BigBear.ai are artificial intelligence (AI) stocks involved in the defense industry. Both companies are also working to move beyond the U.S. government. Two of the leading artificial intelligence (AI) stocks over the past year are Palantir Technologies (NASDAQ: PLTR) and BigBear.ai (NYSE: BBAI).

Motley Fool yesterday

PLTR

BBAI-WS

PYPL
Palantir, JPMorgan Chase Lead Five Stocks Near Buy Points

Palantir Technologies has been getting no shortage of good news from the Trump administration as other contractors struggle.

Investor's Business Daily yesterday

EAT

DASH

COST
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine Regulatory applications have been submitted in the United St

GlobeNewswire yesterday

REGN
Better Artificial Intelligence Stock: BigBear.ai vs. Palantir

The AI data analytics market could be worth more than $1 trillion by 2033. BigBear.ai is trying to carve out its niche in the space, but sales growth has been disappointing. Palantir's sales are climbing and it's profitable, but its stock is pricey.

Motley Fool yesterday

PLTR

BBAI-WS
Better Artificial Intelligence (AI) Stock: Palantir vs. Snowflake

Shares of both Palantir and Snowflake have delivered healthy gains in 2025 despite the broader stock market weakness. Palantir stock has shot up 63% this year despite bouts of volatility. Palantir Technologies helps commercial and government clients integrate generative AI capabilities into their operations with its Artificial Intelligence Platform (AIP), which was launched roughly two years ago.

Motley Fool yesterday

SNOW

PLTR
Is Palantir a Top AI Stock to Buy in June?

Palantir's U.S. growth rate is impressive. Palantir (NASDAQ: PLTR) has rapidly become one of the most popular artificial intelligence (AI) stocks in the market. Few stocks will ever match that sort of jaw-dropping performance, but now, many investors are wondering if it's too late to buy Palantir.

Motley Fool yesterday

PLTR
2 Best Stocks to Buy With $1,000 Right Now

Taiwan Semiconductor expects demand to double in 2025. Amazon is investing more than $100 billion in its artificial intelligence (AI) business this year alone. If you're looking for reliable, low-risk stocks that could deliver outstanding returns over time, I recommend Taiwan Semiconductor (NYSE: TSM) and Amazon (NASDAQ: AMZN).

Motley Fool yesterday

TSM

AMZN
3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now

Nucor is out of favor at the moment in the market, and that's usually a good time to buy this Dividend King steelmaker. Rexford Industrial's laser-like focus has left it open to tariff issues, but the market it invests in is still advantaged. Enterprise Products Partners is a boring energy business, but it makes up for that with a reliable and growing distribution.

Motley Fool yesterday

NUE

EPD

REXR

Performance Overview

Return	300215.SZ	SSE Composite Index (000001.SS)
YTD	-11.30%	-0.13%
1-Year	-16.19%	+8.27%
3-Year	-17.50%	+6.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ELECTRICAL APPARATUS SCIENCE ACADEMY (300215.SZ)

Related News

Dollar General, Lululemon, Broadcom: Earnings to Watch This Week

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi buys US biopharma group Blueprint in $9.1 billion deal

Singapore Dollar Strengthens Slightly, Aided by U.S. Steel, Aluminum Tariffs

Watch These U.S. Steel Stock Price Levels as Trump Plans to Double Steel Tariffs

If EPS Growth Is Important To You, DocuSign (NASDAQ:DOCU) Presents An Opportunity

2 American Companies That Could Be the Winners of Trump's Tariff Wars

Street Calls of the Week

5 Brilliant Stocks to Buy in June

TSMC Stock Maintains High-Conviction AI Play Status With $220 Price Target

MP Materials (NYSE:MP) Reports Q1 Net Loss Despite Increase In REO Production

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial

Better AI Stock: Palantir vs. BigBear.ai

Palantir, JPMorgan Chase Lead Five Stocks Near Buy Points

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Better Artificial Intelligence Stock: BigBear.ai vs. Palantir

Better Artificial Intelligence (AI) Stock: Palantir vs. Snowflake

Is Palantir a Top AI Stock to Buy in June?

2 Best Stocks to Buy With $1,000 Right Now

3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now

Performance Overview